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Abstract: Isoprostanoids are a large family of compounds derived from non-enzymatic oxidation
of polyunsaturated fatty acids (PUFAs). Unlike other oxidative stress biomarkers, they provide
unique information on the precursor of the targeted PUFA. Although they were discovered about
a quarter of century ago, the knowledge on the role of key isoprostanoids in the pathogenesis
of experimental and human disease models remains limited. This is mainly due to the limited
availability of highly purified molecules to be used as a reference standard in the identification
of biological samples. The accurate knowledge on their biological relevance is the critical step that
could be translated from some mere technical/industrial advances into a reliable biological disease
marker which is helpful in deciphering the oxidative stress puzzle related to neurological disorders.
Recent research indicates the value of isoprostanoids in predicting the clinical presentation and
evolution of the neurological diseases. This review focuses on the relevance of isoprostanoids as
mediators and potential biomarkers in neurological diseases, a heterogeneous family ranging from
rare brain diseases to major health conditions that could have worldwide socioeconomic impact in
the health sector. The current challenge is to identify the preferential biochemical pathways that
actually follow the oxidative reactions in the neurological diseases and the consequence of the specific
isoprostanes in the underlying pathogenic mechanisms.
Keywords: isoprostanes; neuroprostanes; neurological diseases; biomarkers
1. Introduction
Over the years, lipid peroxidation went from being a mere indicator of oxidative stress process
in in vitro experimental models to become a reliable marker of oxidative damage in vivo. One major
part of lipid peroxidation is the non-enzymatic/free radical process triggered by the reaction of
lipids with molecular oxygen, creating initial oxidative event that is further amplified through a
series of chain reactions. The chemistry of the free radical–induced lipid peroxidation chain has
been thoroughly reviewed by Yin et al. [1]. Decomposed oxidized lipids (i.e., aldehydes) [2] or
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non-enzymatic oxygenated metabolites (i.e., isoprostanoids) are known as the secondary products
of lipid peroxidation [3]. Isoprostanoids, which are prostaglandin isomers, are derived from
polyunsaturated fatty acids (PUFAs). Unlike enzymatically produced prostaglandins, isoprostanoids
are formed in situ, within the membrane, and released through hydrolysis via phospholipase A2
(PLA2) [4].
Despite the growing interest in the product of protein gene expressions and molecular biology
techniques, that are related to the complex signal transduction process, scientists should bear in mind
that lipids are core components of the cell membrane in maintaining cellular structure and function.
Among the omics tools including genomics, transcriptomics, and metabolomics, lipidomics is
prevalent in elucidating the pathogenesis of human diseases associated to lipids [5] and also in
the development of precision medicine, which requires molecular diagnostic tests. In retrospect,
the contradiction to lipidomics of isoprostanoids is influenced by cyclooxygenase-2 (COX-2) reaction
products [5]. Nevertheless, isoprostanoids are investigated to identify the biological involvement and
its role in the pathogenic pathways.
2. Relevance for Lipids in Brain
Lipids, in particular phospholipids, are involved in maintaining the functionality of neuronal cell
membrane where the synaptic transmission depends on. For instance, synaptic phospholipids have
been suggested as a new target for cortical hyperexcitability in psychiatric disorders [6], and synaptic
lipid signaling has been shown to be involved in the glutamatergic transmission in the somatosensory
cortex [7], where an alteration has been evoked in the pathophysiology of psychiatric disorder [8]. In the
aging brains of healthy individuals, an association between changes in neuronal electrical excitability
and the oxidation of membrane lipids appears to be related in the decline of learning and memory
performance. A hypothetical explanation would lie in the fact that processes triggered by free radical
and oxidant reactions on the lipid moiety would contribute to the age-related deterioration of the
nervous system by damaging the phospholipids of the cell and organelle membranes. Since the
peroxidized portion of the PUFAs are excised from the phospholipid by PLA2 enzymes, it has
been proposed that the balance between PLA2 and redox status would determine the rate of lipid
peroxidation in the membrane and perhaps affect and deteriorate the PLA2-dependent neuronal
excitability and plasticity [9].
When searching for a biomarker related to diseases, the general trend is to attempt to identify
a specific protein even though the lipid portion can be equally agreeable for the identification,
especially in neurological diseases due to the high lipid content in the brain. In this regard, the relevance
of lipidomics as a novel method to identify biomarkers in early detection and diagnostic criteria
for Alzheimer’s disease was recently reviewed [10], and furthermore, mass spectrometry–derived
lipidomic profiles appeared to be different in individuals with and without cognitive impairment [11].
Therefore, complete or targeted lipidomics appears to be a relevant approach in search of biomarkers,
but it is relatively unexplored when compared to the large clinical application for proteomics.
In lipid metabolism, dietary essential n-3 and n-6 polyunsaturated fatty acids (PUFAs),
namely α-linolenic acid (ALA, 18:3n-3) and linoleic acid (LA, 18:2n-6), play crucial roles in maintaining
tissue levels [12]. However, docosahexaenoic acid (DHA; 22:6, n-3), and arachidonic acid (AA; 20:4,
n-6), from the diet are more important PUFAs as they are abundant in the brain and vital components
of the neuronal phospholipids. Further, in n-6 PUFA metabolism, adrenic acid (AdA; 22:4, n-6) is
produced by elongation of AA and concentrated in the myelin sheath within the brain white matter
of the primates. PUFAs are esterified in situ to phospholipids and in particular, DHA, AA, and AdA
(Figure 1) are crucial components of neuronal or glia phospholipids.
PUFAs are related to the physiological developmental of the neurological system in the brain
when considering the pathogenesis related to neuroplasticity, neurogenesis, and synaptogenesis [13].
In relation, nutritional n-3 PUFAs deficiency, especially during the perinatal period, alters neuronal
plasticity [14]. Moreover, it is suggested that a good balance of n-3/n-6 PUFA ratio protects the
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cognitive deficits induced by neuroinflammation [15], and furthermore enrichment of n-3 PUFAs
mediate mechanisms involved in learning memory performance [16].
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Figure 1. Chemical structures of key polyunsaturated fatty acids related to neuronal phospholipids. Figure 1. Che ical str ct res of key olyunsaturated fatty acids related to neuronal phospholipids.
As shown in the brain of rodents, DHA and AA distribution is region–specific and needed for
brain function and development [17]. In particular, DHA promotes neuroplasticity, neurogenesis,
synaptogenesis and neuroimmune interactions [18,19]. In a recent report, enriched brain levels of
DHA by genetic conversion of n-6 PUFA to n-3-PUFA led to increased hippocampal neurogenesis [20].
Neurogenesis was also increased in the hippocampus of aged rats supplemented with DHA [19].
On the other hand, Coti Bertrand et al., demonstrated that neurogenesis was decreased in brain of
DHA-deficient embryonic rat [21].
3. Relevance of Lipid Peroxidation Products in Neurodegeneration
In brain, lipid peroxidation products, namely malondialdehyde (MDA), protein-bound acrolein
adduct, and isoprostanoids, are reported to be elevated in the progression of Alzheimer’s disease
(AD) from the earliest to the late stages and were also detected in mild cognitive impairment (MCI)
conditions [22]. As a result, these products are currently suggested to contribute to neurodegeneration.
In addition, immunochemical detection of lipid hydroperoxide- and aldehyde-modified proteins,
and selective protein targets of aldehydes were found in AD [23,24]. Nevertheless, relationships
between lipid peroxidation products and key clinical AD features remain to be confirmed.
Of note in this review is the uniqueness of isoprostanoids in neurodegeneration. Through interaction
of radical species, such as radical oxygen species (ROS), PUFAs undergo a series of non-enzymatic
lipid peroxidation and generate specialized lipid mediators such as F2-isoprostanes (F2-IsoPs),
F2-dihomo-isoprostanes (F2-dihomo-IsoPs), and F4-neuroprostanes (F4-NeuroPs) from AA, AdA,
and DHA, respectively. Among all the isoprostanoids identified so far, the chemical structures related
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The result of cyclization process in AA oxidation forms four series comprising of 5-, 8-, 12-,
and 15-F2-Isoprostanes (IsoP). F2-IsoPs have been defined as the gold standard marker of lipid
peroxidation in vivo for their relevance in several human diseases, including neurodegenerative
disease [29,30].
Moreover, AdA oxidation form four series of regioisomers (7-, 10-, 14-, and 17-series) [31],
and were detected in AD patients [31,32], and also in Rett syndrome (RTT) [25], Down syndrome [33],
and epileptic [34] patients. The myelin sheath is concentrated with AdA and F2-dihomo-IsoPs have
been suggested to be specific in assessing the extent of free radical damage of the myelin [31]. Likewise,
F4-NeuroPs measurements are relatively specific to oxidative damage of the neuronal membranes
due to abundant DHA in the brain gray matter [35,36]. In this regard, F4-NeuroPs, and not F2-IsoPs,
were proposed to be the critical group of oxidized DHA products for neuronal damage [37–39].
F2-IsoPs and F4-NeuroPs were also investigated as biomarkers to explore the role of the oxidative
damage in the pathogenesis of Parkinson’s disease [28]. In such neurological conditions, plasma levels
of F2-IsoPs and F4-NeuroPs provided evidence that peripheral indices of oxidative damage are elevated
at different stages of the disease [28].
Non-enzymatic DHA oxidation generates eight regioisomer series (4-, 7-, 10-, 11-, 13-, 14-, 17- or
20-series). Among all the F4-NeuroP molecules, a few isomers were characterized in neuro-pathological
conditions, and so far, 4-F4t-NeuroPs and 10-F4t-NeuroPs are the most represented [3,27,34,40].
Since 1999, F4-NeuroPs have been investigated as specific marker of DHA peroxidation in AD [41],
and the interest in such matter is continuing [42]. Notably, the debate on the use of nutraceutical
intervention specifically, DHA supplementation is ongoing. In this regard, PUFAs and DHA levels are
reported to be associated to reduced risk of AD. Nevertheless, lipid peroxidation products of n-3-PUFA
have been associated to increased levels of β-amyloid peptide in in vitro studies [43], indicating that
biological activities are stimulated by oxidized DHA and should be asserted in nutrition related studies.
Considering this, caution must also be made in scientific experimentations as PUFAs are prone to
oxidation in in vitro, whereas supplementation of PUFA reduce in vivo oxidative stress by lowering
F2-IsoPs levels [44,45]; the two outcomes may not be complementary.
Overall, PUFAs and their oxygenated metabolites of non-enzymatic lipid peroxidation have
been investigated as potential biomarkers and/or therapeutic target in different neurological diseases.
The measurement of F2-IsoPs can be accurately carried out in all body fluids by mass spectrometric
analyses [46,47]. Currently, such detections are performed to evaluate the occurrence of lipid
peroxidation events in numerous diseases including neurodegenerative diseases [48–50]. Nevertheless,
it has been focused on the possibility that single F2-IsoPs measurements could represent “spot”
measurements of lipid peroxidation process rather than understanding the real biological role of
the isoprostanoids [51]. As a biomarker, detection of different isomers and/or metabolites [29] and
repeated measurements over time of such oxidized lipid products should be carried out to reinforce
and validate for their role as biomarkers. Such assessment so far has been executed in Rett (RTT)
syndrome where marked increased levels of isoprostanoids have been detected in typical RTT at every
clinical stages of the disease [52].
4. Mechanisms Underlying Different Brain Diseases: Similar but Not the Same
Isoprostanoids, mainly F2-IsoPs, have been detected to be elevated in different neurological
diseases from distinct etiological causes [36,53–55]. Due to the broad and general understanding of
the isoprostanoids, they are repeatedly neglected for its specificity and often considered nonspecific
indicators of oxidative damage. Nevertheless, F2-IsoP formation appeared to be modulated by specific
mechanisms in the neurological diseases arising from methyl-CpG binding protein 2 (MECP2) gene
expression, the so-called MECP2-pathies [56].
Isoprostanoid formation appears to be intimately linked to disorders of neurodevelopmental caused
by alterations in the methyl-CpG binding protein 2 (MECP2) gene expression. In neurodevelopmental
disorders, it is linked to under-or over-expression of MECP2 gene, such as in RTT and MECP2
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duplication syndrome (MDS), where isoprostanoids formation have been shown to be specifically
related to different MECP2 gene mutations [25,26,52,57–59] (Table 1).
Moreover, in symptomatic RTT mice (Mecp2 stop/y model), the amounts of 4-F4t-NeuroP and
10-F4t-NeuroP in brain tissue have been shown to be significantly higher than the wild-type, and highly
correlated to the phenotypic severity [27].
Table 1. Isoprostanoids formation is related to altered MECP2 gene expression.
Neurodevelopmental Disorders Caused by







Rett Syndrome (RTT) + a + b + c
Most frequent MECP2 mutations in RTT:
R106W ↔ b ↔ b
R 133C ↔ b ↔ b
T158M +++ b ↔ b
R168X +++ b +++ b
R255X +++ b +++ b
R270X +++ b ++ b
R294X ↔ b ↔ b
R306X ↔ b ↔ b
C-terminal deletions ↔ b ↔ b
Large deletions ↔ b ++ b
MECP2 duplication syndrome (MDS) ++ d ++ d ↔ d
Legend: ↔, not significantly different as compared to control subjects; +, ++ and +++, increased highly increased
and very highly increased, respectively, as compared to control subjects; C TER D, C terminal deletion; L DEL,
large MECP2 (methyl-CpG binding protein 2) gene deletion. a Leoncini et al. (2011) [58]; Signorini et al. (2014) [59];
De Felice et al. (2009) [26]; b Signorini et al. (2011) [52]; c De Felice et al. (2011) [25]; d Signorini et al. (2016) [57].
RTT, which is due to de novo mutations in MECP2 gene, features transient autistic-like phase [60]
and has been recognized as model of neurodevelopmental disorders [61]. However, RTT is a
progressive neurological disorder and not degenerative. Considering this, it is conceivable that
various progressive neurological conditions, even on a degenerative basis, may share similar oxidative
mechanisms. Usually, such common mechanisms involve the formation of isoprostanoids, albeit with
their own specificity. Indeed, not only the products of the non-enzymatic lipid peroxidation but also the
oxidation pathways were found to be relevant in previous studies (Table 1). By identifying the isomers
that are synthesized in different oxidation pathways of the PUFA, one is able to (i) understand the time
course of disease mechanisms, (ii) identify molecular targets (i.e., therapeutic target), and (iii) know
the relationship with the clinical manifestations. Therefore, the availability of chemically synthesized
molecules is crucial to test the clinical relevance of non-enzymatic oxidized products of PUFA.
5. In Search of a Biomarker: Isoprostanoids as Biomarkers in Neurological Diseases
Unlike other oxidative stress biomarkers, isoprostanoids provide unique information on the
precursor and/or the targeted PUFA. Accordingly, isoprostanoid formation identifies which PUFA
precursor is affected by the non-enzymatic oxidative process. Thus, F2-IsoP, F4-NeuroP, and F2-dihomo-
IsoP levels are not only specific indices of oxidative stress but also markers of biological oxidative
damage involving specific PUFAs.
According to the criteria for an ideal biomarker, it should be quantifiable to characterize a
biological process and to predict clinical results, even after diet or drug intervention [62]. In particular,
an ideal biomarker of oxidative damage (i) should detect a major part of total ongoing oxidative
damage in vivo, (ii) should be measured employing robust technology, (iii) should not be confounded
by diet, and (iv) should be stable on storage [63]. Indeed, several studies showed isoprostanoids do
meet such criteria for neurological diseases [25,28,38,52]. Previous studies tested the non-enzymatic
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oxygenated metabolites of lipid peroxidation (i) in different pathologies [27,57,64], (ii) in groups of
subjects at different ages [25], (iii) in relation to the severity of the disease [52,58], (iv) in relation to the
pre-symptomatic clinical status of the disease [38], (v) in animal models [38], and (vi) in relation to
drug treatment/supplementation [65].
In view of biomarkers as useful tools to identify targeted therapeutic treatment and drug
development processes, knowledge of the molecular precursors of isoprostanoids has led to the
experimentation of n-3 PUFAs supplementation in RTT. In subject treated with what specifically,
a significant decrease in the non-enzymatic oxygenated metabolites of lipid peroxidation was observed,
and a clinical improvement was found [52,59,65]. In these investigations [52,59,65], n-3 PUFA
supplementation was not merely considered as a simple antioxidant treatment or a component in
generic antioxidant defense; rather these studies interpreted n-3 PUFAs as biomolecules enriched in
the brain lipids to prevent degeneration of the pathophysiological processes of the disease.
When considering the outcome of neural related diseases, it is crucial to consider the
method of measurement as it needs to be sensitive enough for detection in order to avoid
misinterpretation of data from rare samples. Currently, measurements of isoprostanoids in biological
samples are widely carried out by mass spectrometry (MS), singly or tandem (MS/MS) such
as gas chromatography—mass spectrometry (GC-MS), GC-MS/MS, liquid chromatography–mass
spectrometry (LC-MS), and LC-MS/MS [66]. These accredited techniques for isoprostanoid
determination in biological samples have advantages and disadvantages. Although identifications
of the investigated molecules are specific and sensitive at low quantities (i.e., in the order of the
picograms), it can be costly and time consuming. Furthermore, isoprostanoids are composed of
numerous types of isomers due to hydrogen abstraction and molecular oxygen addition in the PUFA
oxidation process, therefore it is necessary to unravel the molecular rearrangement of oxidized PUFA
products mainly derived from AA, DHA, and AdA [31,67,68] that are richly found in the neurons.
The available scientific literature on F4-NeuroP and F2-dihomo-IsoP remains limited. This is
mainly due to the limited availability of purified molecules to be used as reference compounds
in the identification of isoprostanoids in biological samples, which is an indispensable step in
the exploration of the cause-effect relationship between the neurological damage and the levels
of isoprostanoids in the bloodstream or in other fluids and tissues. Nevertheless, assays performed in
plasma or urine samples are proving useful to predict clinical presentation/evolution of neurological
diseases [25,27,31–34,38,52,57,59,69,70] (Table 2). Plasma 10-F4t-NeuroP and 4-F4t-NeuroP levels were
shown to be useful to discriminate between different brain diseases and the association to clinical
severity appeared to be distinctive for different neurological conditions, thus suggesting that in vivo
DHA oxidation follows preferential chemical rearrangements according to different human brain
diseases. Consequently, the abundance of plasma 4-F4t-NeuroP and 10-F4t-NeuroP is able to predict
disease severity (Table 3).
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Table 2. F4-NeuroP and F2-dihomo-IsoP detection in different human and experimental brain disease models.
Human and Experimental Brain Disease Models Sample PUFA Non-Enzymatic Oxidized Products Methodology References
Human Brain Disease
Alzheimer’s Disease
urine F2-IsoPs, F2-dihomo-IsoPs, F4-NeuroPs LC–MS/MS García-Blanco et al. (2018) [32]
brain F2-IsoPs, F2-dihomo-IsoPs, F4-NeuroPs GC-MS VanRollins et al. (2008) [31]
Multiple sclerosis, Autism spectrum disorders,
Rett syndrome, Down syndrome plasma 4(RS)-4-F4t-NeuroP and 10(RS)-10-F4t-NeuroP GC-MS/MS Signorini et al. (2018) [27]





HPLC-MS/MS Medina et al. (2015) [34]
Traumatic brain injury cerebrospinal fluid Isofurans, F4-NeuroPs, F2-IsoPs GC-MS Corcoran et al. (2011) [70]
Rett syndrome plasma F4-NeuroPsent-7(RS)-F2t-dihomo-IsoPs, 17-F2t-dihomo-IsoPs.
GC-MS/MS
Signorini et al. (2011) [52]
Signorini et al. (2014) [59]
De Felice et al. (2011) [25]
MECP2 duplication syndrome plasma F4-NeuroPs GC-MS/MS Signorini et al. (2016) [57]
Experimental Brain Disease




GC-MS/MS Signorini et al. (2018) [27]De Felice et al. (2014) [38]
Legend: F2-IsoPs, F2-isoprostanes; F4-NeuroPs, F4-neuroprostanes; F2-dihomo-IsoPs, F2-dihomo-isoprostanes; GC-MS, gas chromatography-mass spectrometry; GC-MS/MS,
gas chromatography–tandem mass spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; PUFA: polyunsaturated fatty acid.
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Table 3. Plasma 4(RS)-4-F4t-NeuroP and 10(RS)-10-F4t-NeuroP abundancy and disease severity.
Human Disease F4-NeuroPs
Plasma F4-NeuroP


































Although  they are known about a quarter of century ago,  the knowledge on  the key  role of 
isoprostanoids in the pathogenesis of experimental model and human diseases remain limited. Here, 
we summarized the current evidence on the role of isoprostanoids in the clinical presentation and 
evolution of  several neurological diseases,  ranging  from very  rare brain diseases  to major health 
conditions  taking  into  the  account  of worldwide  socioeconomic  impact  (Figure  3).  The  current 
challenge is to identify the preferential biochemical pathways that actually follow oxidative reactions 
in  the biological  systems and,  consequently,  the  identification of  the  specific  isoprostane  isomers 
related  to  the underlying pathogenic mechanism.  It  is  clear  that  the  accurate  knowledge  on  the 
biological  relevance  of  these  molecules  is  the  critical  step  that  could  be  translated  as 
technical/industrial advances of reliable biological disease markers and potentially aid in predicting 
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Autism spectrum isorders + a ↔ a
Rett syndrome + a ++ a
Multiple Sclerosis +++ a ++++ a
Legend: ↔, not significantly different as compare to control subjects; +, ++, +++, and ++++, increased,
highly increased, very highly increased, a d extremely increased respectively, as compared to control subjects.
a Signorini et al. (2018) [27].
6. Conclusions and Future Research
Although they are known about a quarter of century ago, the knowledg on the k y rol of
isoprostanoids in the pathogenesis of experimental model and human diseases remain limited. Here,
we summarized the current evidence on the role of isoprostanoids in the clinical presentation and
evolution of several neurological diseases, ranging from very rare brain diseases to major health
conditions taki int the account of wor dwid socioeconomic impact (Figure 3). The current
challenge is to identify the preferential biochemical pathways that actually follow oxidative reactions
in the biological systems d, c nsequ ntly, the identification of the specific isoprostane isomers rel ted
to the und rlying pathogenic mechanism. It is clear that th accurate knowledge on the biological
relevance of these molecules is the critical step that could be translated as technical/industrial advances
of reliable biological disease markers and potentially aid in predicting the clinical progression and
deciphering in the oxidative stress puzzle related to neurological disorders.
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